Published in AIDS on June 19, 2010
Host genetic factors predisposing to HIV-associated neurocognitive disorder. Curr HIV/AIDS Rep (2014) 0.88
Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system. J Cell Physiol (2012) 0.82
A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med (1989) 2.95
HIV dementia: an evolving disease. J Neuroimmunol (2004) 2.88
HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med (1998) 2.68
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A (2008) 2.38
CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol (2001) 2.30
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res (2008) 2.28
Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem (1982) 2.19
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet (1997) 1.92
Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol (2000) 1.30
Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol (1996) 1.30
Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. J Biol Chem (1985) 1.28
CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res Hum Retroviruses (2008) 1.22
Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol (2006) 1.20
APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging (2002) 1.20
APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS (2010) 1.12
Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis (2010) 1.06
APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol (2004) 1.04
The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med (2008) 1.01
An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol (2008) 0.97
Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses (2004) 0.90
Recent development of cognitive and neuropsychological assessment in Asian countries. Psychol Assess (2003) 0.90
Effects of apolipoprotein E on the human immunodeficiency virus protein Tat in neuronal cultures and synaptosomes. J Neurosci Res (2004) 0.89
Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol Immunol (2009) 0.86
Frequency of apolipoprotein E4 among older compared with younger HIV patients: support for detrimental effect of E4 on survival. Proc Natl Acad Sci U S A (2008) 0.86
Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. N Engl J Med (2005) 1.85
Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol (2008) 1.74
Delayed fingolimod-associated asystole. Mult Scler (2011) 1.61
Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol (2007) 1.52
High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J Clin Microbiol (2006) 1.34
Macrophage/microglial accumulation and proliferating cell nuclear antigen expression in the central nervous system in human immunodeficiency virus encephalopathy. Am J Pathol (2004) 1.28
Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol (2004) 1.27
Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med (2005) 1.24
The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci (2007) 1.23
CD163/CD16 coexpression by circulating monocytes/macrophages in HIV: potential biomarkers for HIV infection and AIDS progression. AIDS Res Hum Retroviruses (2008) 1.22
Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem (2009) 1.21
Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol (2015) 1.21
HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology (2011) 1.17
Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol (2004) 1.15
ALS syndrome in patients with HIV-1 infection. J Neurol Sci (2005) 1.14
Stroke in HIV infection and AIDS. Expert Rev Cardiovasc Ther (2009) 1.09
Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes. J Neuroimmunol (2005) 1.07
Update on progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep (2012) 1.06
Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis (2004) 1.04
Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol (2002) 1.03
Mass lesions of the brain in AIDS: the dilemmas of distinguishing toxoplasmosis from primary CNS lymphoma. AJNR Am J Neuroradiol (2003) 1.02
Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma (2012) 1.02
Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J Immunol (2003) 1.01
Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci U S A (2008) 1.00
Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr (2004) 0.98
Regulation of complement component C3 in astrocytes by IL-1beta and morphine. J Neuroimmune Pharmacol (2007) 0.95
Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother (2003) 0.95
Isolated Histoplasma capsulatum meningoencephalitis in an immunocompetent child. J Child Neurol (2012) 0.94
Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci (2002) 0.94
Neuroprotective effects of IGF-I against TNFalpha-induced neuronal damage in HIV-associated dementia. Virology (2003) 0.93
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol (2009) 0.93
The bone marrow, B cells, and JC virus. J Neurovirol (2008) 0.93
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol (2010) 0.93
Internalization of exogenous human immunodeficiency virus-1 protein, Tat, by KG-1 oligodendroglioma cells followed by stimulation of DNA replication initiated at the JC virus origin. DNA Cell Biol (2004) 0.92
Anti-cytokine therapeutics: history and update. Curr Pharm Des (2009) 0.92
T-cell and neuronal apoptosis in HIV infection: implications for therapeutic intervention. Int Rev Immunol (2003) 0.91
Macrophage colony-stimulating factor in the pathogenesis of HIV infection: potential target for therapeutic intervention. J Neuroimmune Pharmacol (2006) 0.90
Steroids for PML-IRIS: a double-edged sword? Neurology (2009) 0.89
Early establishment and antigen dependence of simian immunodeficiency virus-specific CD8+ T-cell defects. J Virol (2007) 0.89
SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the Tat protein of human immunodeficiency virus type 1. J Gen Virol (2009) 0.88
Role of Puralpha in the modulation of homologous recombination-directed DNA repair by HIV-1 Tat. Anticancer Res (2008) 0.88
Central Nervous System Infections With Immunomodulatory Therapies. Continuum (Minneap Minn) (2015) 0.87
Activation of HIV-1 LTR by Rad51 in microglial cells. Cell Cycle (2010) 0.87
Evidence for the involvement of Puralpha in response to DNA replication stress. Cancer Biol Ther (2007) 0.87
Low prevalence of varicella zoster virus and herpes simplex virus type 2 in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.87
T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection. DNA Cell Biol (2004) 0.87
Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine (2005) 0.87
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids following influenza vaccination. Arch Pathol Lab Med (2012) 0.86
The basis for modeling progressive multifocal leukoencephalopathy pathogenesis. Curr Opin Neurol (2011) 0.86
Puralpha as a cellular co-factor of Rev/RRE-mediated expression of HIV-1 intron-containing mRNA. J Cell Biochem (2008) 0.86
A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol (2006) 0.86
Wernicke's encephalopathy in the course of chemoradiotherapy for head and neck cancer. Am J Otolaryngol (2010) 0.86
Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep (2013) 0.85
Complications of immunosuppressive/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol (2012) 0.85
Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy (2006) 0.85
Interaction between the pura and E2F-1 transcription factors. Anticancer Res (2004) 0.84
Cross-interaction between JC virus agnoprotein and human immunodeficiency virus type 1 (HIV-1) Tat modulates transcription of the HIV-1 long terminal repeat in glial cells. J Virol (2006) 0.84
Effect of target cell availability on HIV-1 production in vitro. AIDS (2002) 0.84
Monofocal acute inflammatory Demyelination (MAID): a unique disorder simulating brain neoplasm. South Med J (2002) 0.84
JCV-specific CD4 T cell response: another piece of the puzzle in explaining some aspects of AIDS associated PML. AIDS (2003) 0.83
Cross talk between growth factors and viral and cellular factors alters neuronal signaling pathways: implication for HIV-associated dementia. Brain Res Brain Res Rev (2005) 0.83
Role of C/EBP-β, p38 MAPK, and MKK6 in IL-1β-mediated C3 gene regulation in astrocytes. J Cell Biochem (2011) 0.83
Dysregulation of NGF-signaling and Egr-1 expression by Tat in neuronal cell culture. J Cell Physiol (2006) 0.83
Progressive Multifocal Leukoencephalopathy: Recent Advances and a Neuro-Ophthalmological Review. J Neuroophthalmol (2015) 0.83
Persistent anti-gag, -Nef, and -Rev IgM levels as markers of the impaired functions of CD4+ T-helper lymphocytes during SIVmac251 infection of cynomolgus macaques. J Acquir Immune Defic Syndr (2005) 0.82
Infection risk in patients on multiple sclerosis therapeutics. CNS Drugs (2015) 0.81
Spinal epidural abscess. Curr Infect Dis Rep (2014) 0.81
Substantia nigra depigmentation and exposure to encephalitis lethargica. Ann Neurol (2012) 0.81
Alien hand syndrome. Neurology (2006) 0.81
Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses. DNA Cell Biol (2002) 0.80
Inhibition of NF-κB activity by HIV-1 Vpr is dependent on Vpr binding protein. J Cell Physiol (2013) 0.80
Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques. J Neuroimmunol (2013) 0.80
Cervical myelopathy secondary to violent tics of Tourette's syndrome. Neurology (2003) 0.79
Neuronal ferritin heavy chain and drug abuse affect HIV-associated cognitive dysfunction. J Clin Invest (2014) 0.79
Introduction to HIV infection and neuro-AIDS. Handb Clin Neurol (2007) 0.79
Disease-modifying drugs for multiple sclerosis and JC virus expression. J Neurovirol (2012) 0.79
The changing landscape of progressive multifocal leukoencephalopathy. Curr Infect Dis Rep (2011) 0.79
The manifold faces of PML and the challenge of diagnosis. Neurology (2011) 0.79
T-cell receptor excision circles (TREC) and maintenance of long-term non-progression status in HIV-1 infection. AIDS (2003) 0.79
An international screening tool for HIV dementia. AIDS (2005) 0.78
Autoimmune markers in HIV-associated dementia. J Neuroimmunol (2003) 0.78
Genomic approach of AIDS pathogenesis: exhaustive genotyping of the TNFR1 gene in a French AIDS cohort. Biomed Pharmacother (2005) 0.78
Reply to "'Thinking without thinking' about natalizumab and PML". J Neurol Sci (2007) 0.78
CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines. Anticancer Res (2012) 0.77
Macrophage colony stimulating factor regulation by nuclear factor kappa B: a relevant pathway in human immunodeficiency virus type 1 infected macrophages. DNA Cell Biol (2011) 0.77
Analysis of IGG and IGG4 in HIV-1 seropositive patients and correlation with biological and genetic markers. Biomed Pharmacother (2005) 0.77
Too much of a good thing? IRIS with natalizumab-associated PML. Neurology (2011) 0.77
Primary lateral sclerosis with HIV-1 infection. Neurology (2008) 0.77
HIV and the central nervous system. Compr Ther (2002) 0.77
Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Circulation (2002) 0.77
Identification of potential antibody markers in HIV-associated dementia. J Neuroimmunol (2004) 0.76
Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res (2003) 0.76
Cellular Interactions and Signaling in neuroAIDS: Emerging Issues Colloquium. J Neuroimmune Pharmacol (2014) 0.76
Parinaud syndrome heralding MS. Neurology (2003) 0.75
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man. J Neurovirol (2014) 0.75
Is the presence of antibodies in CSF sufficient to make a definitive diagnosis of Lyme disease? Neurology (2007) 0.75
Memory and the mammillothalamic tract. AJNR Am J Neuroradiol (2004) 0.75
HIV cure strategists: ignore the central nervous system at your patients' peril. AIDS (2017) 0.75
Design, targeting, and initial screening of sTRSV-derived hairpin ribozymes for optimum helix 1 length and catalytic efficiency in vitro. Methods Mol Biol (2004) 0.75